Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Kidney Int. 2014 Nov;86(5):1057-8. doi: 10.1038/ki.2014.246.

¹ Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
² Division of Endocrinology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
³ Boehringer Ingelheim Canada Ltd/Ltée, Burlington, Ontario, Canada.
⁴ Kidney Research Centre, Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
⁵ Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
⁶ Boehringer Ingelheim Norway KS, Asker, Norway.
⁷ Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.

No abstract available

Publication types